Outlook Therapeutics News

Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the authorization of

GlobeNewswireMay 13 20:50

Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment

GlobeNewswireMay 9 20:45

Outlook Therapeutics to Present at the Retina World Congress 2024

ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment

GlobeNewswireMay 2 21:05

Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevaciz

GlobeNewswireApr 29 21:00

Outlook Therapeutics Files to Sell 2.78M Shares of Common Stock for Holders

Seeking AlphaApr 27 04:40

Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors -- Barrons.com

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen

Barron'sApr 26 18:37

Press Release: Outlook Therapeutics(R) Announces Closing of Private Placement of $5.0 Million

Outlook Therapeutics(R) Announces Closing of Private Placement of $5.0 Million ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company

Dow JonesApr 16 04:15

Outlook Therapeutics Files Prospectus Supplement Related To Offer, Sale Of Up To $93.7M Of Common Stock That May Be Sold Under Sales Agreement

Outlook Therapeutics Files Prospectus Supplement Related To Offer, Sale Of Up To $93.7M Of Common Stock That May Be Sold Under Sales Agreement

BenzingaApr 13 04:33

Insiders Are Piling Into These 10 Healthcare Stocks in 2024

Yahoo FinanceApr 11 03:30

Insiders Buying Outlook Therapeutics And 2 Other Stocks

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the st

BenzingaApr 1 22:46

Outlook Therapeutics(OTLK.US) Director Buys US$22,241.83 in Common Stock

$Outlook Therapeutics(OTLK.US)$ Director Haddadin Yezan Munther purchased 1,881.71 shares of Common Stock on Mar 28, 2024 at an average price of $11.82 for a total value of $22,241.83.Source: Announce

Futu NewsMar 29 23:20

Outlook Therapeutics Files for $300M Mixed Securities Shelf

Seeking AlphaMar 29 05:15

Tang Capital Partners Discloses 9.99% Passive Stake In Outlook Therapeutics

Tang Capital Partners Discloses 9.99% Passive Stake In Outlook Therapeutics

BenzingaMar 29 04:16

Outlook Therapeutics Shares Rise After BTIG Upgrade

Outlook Therapeutics (OTLK) shares rose 9% in recent trading Wednesday after BTIG upgraded its rating on the stock to buy from neutral. Trading volume topped 1.31 million shares versus the daily avera

MT NewswiresMar 28 03:38

Outlook Therapeutics Raised to Buy From Neutral by BTIG

Outlook Therapeutics Raised to Buy From Neutral by BTIG

Dow JonesMar 27 19:27

BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target

BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $50 price target.

BenzingaMar 27 19:19

Buy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Target

TipRanksMar 27 18:45

Outlook Therapeutics Grants Stock Options to Top Executives

TipRanksMar 27 04:33

Outlook Therapeutics Reports Secondary Share Offering

Outlook Therapeutics (OTLK) reported late Monday its stockholders may sell up to about 21.43 million shares, including some 12.86 million shares issuable upon the exercise of warrants, with the filing

MT NewswiresMar 26 05:24

Outlook Therapeutics Files to Sell 21.43M Common Shares for Holders

Seeking AlphaMar 26 04:54